PUMA
Globally renowned sports brand, PUMA, proudly unveiled the highly anticipated Jamaican Olympic Association kits during an unmissable showcase of speed at the ISSA Boys & Girls Championships in Kingston, Jamaica.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240324802511/en/
Sports company PUMA unveiled the Jamaican Olympic Association kits at the ISSA Boys & Girls Championships in Kingston, Jamaica. (Pictured: Shanieka Ricketts) (Photo: Business Wire)
The reveal, at the Jamaica National Stadium, came in front of more than 25,000 track enthusiasts from across the country, all gathering to feast their eyes on the future of Jamaican track & field. It served as the perfect platform to showcase the cutting-edge apparel that will adorn the fastest athletes on the planet this summer in Paris – many of whom competed at this event in their teenage years.
Jamaica’s most prestigious athletes took centre stage for the grand reveal, including the likes of double, double Olympic Champion, Elaine Thompson-Herah; the fastest woman alive at the 200 meters, Shericka Jackson; reigning Olympic Champion at the 110m hurdles Hansle Parchment; the second fastest man of all-time, Yohan Blake; former 100m World Record holder, Asafa Powell; World U-20 Triple Jump Champion Jaydon Hibbert; Rushell Clayton, Ackeem Blake and many more. They were joined side-by-side on the track by young athletes from PUMA sponsored high schools.
The ISSA Boys & Girls Championships, often referred to as "Champs," has gained immense popularity and recognition for its ability to showcase young Jamaican talent who have gone on to achieve greatness on both the domestic and international stage. The Championships not only celebrate sporting excellence but also serve as a symbol of unity, passion and pride for the Jamaican community.
"Champs is the beating heart of Jamaica. For decades, it has produced an unimaginable number of Olympians, World Champions and World Record holders, who themselves have created some of the most memorable moments in sports history. Tonight, here in Kingston, we created another,” said PUMA's Chief Executive Officer, Arne Freundt.
The new designs represent a perfect harmony of speed and fashion, reflective of the symbiotic relationship between these two giants of track & field.
Rooted in elite performance, they have been designed to evoke speed with cut lines strategically placed to accentuate the physique of the athletes whilst also providing a showstopping visual via Warpspeed graphics that emphasise the beauty of an athlete in motion. Engineered jacquard fabric is ergonomically shaped to contour the back muscles for heat reduction and breathability, with thermoadapt technology regulating body temperature to enable optimum performance.
“In their truest form these kits are an expression of speed. Speed has always been PUMA’s vantage point. It is what enables us to see the game differently, challenge convention and create moments that will live with us forever. We can’t wait to experience more in Paris this summer,” added Arne.
Maria Valdes, Chief Product Officer at PUMA, commented: “What makes these kits special is how closely they have been created in collaboration with our athletes. They are more than just a kit – they are a statement of the collective ambition shared between PUMA and Jamaica. They are a symbol of pride for the PUMA family, and we hope that they become a symbol of pride for Jamaicans this summer and long into the future.”
To find out more about PUMA follow @pumarunning on Instagram.
PUMA
PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For more than 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 21,000 people worldwide, and is headquartered in Herzogenaurach/Germany.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240324802511/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
